Neuro Athletics is a twice-weekly newsletter designed specifically for high-performing men and women who want science-backed strategies to optimize brain health, performance, and longevity. If you’re not already subscribed, join 69,000+ people who receive actionable insights directly in their inbox each week.
Team,
He carries two copies of ApoE4 — the highest genetic risk factor for Alzheimer’s disease. He went through medical school at Harvard knowing exactly what that meant. His LDL sits at 700. Every guideline in medicine says he should be on aggressive lipid-lowering therapy. Every cardiologist he’s consulted has told him he’s a dead man walking.
He got a coronary CT angiogram. Then he waited seven years. Then he got another one.
Zero plaque.
Nick Norwitz is a physician-scientist who decided the consensus was wrong, ran the experiment on himself, and then published the case report so the rest of us could argue about it. He is either the most reckless doctor in America or the most honest one. Possibly both.
In this conversation, we go deep on the ApoE4 paradox — why carriers burn through DHA faster than everyone else, why standard fish oil supplements fail them, and why the phospholipid form of omega-3 reaches the brain through a completely different transport system. Nick explains the Mfsd2a transporter, why it matters more than dose, and what he personally takes.
Then we get into what I think is the most underappreciated target in Alzheimer’s research today: GSK-3 beta. This is the enzyme that phosphorylates tau. Nick lays out the lithium orotate data — the same data that sold out supplement shelves worldwide after he posted about it — and explains why low-dose lithium may be doing something fundamentally different from what psychiatrists use it for.
The second half of the conversation is where it gets controversial. Nick makes the case that metabolically healthy individuals with elevated LDL may not benefit from statins. He walks through the EZPAVE trial — the one that made headlines — and explains why the data doesn’t say what the headlines claimed. We talk about what actually causes heart disease in someone who is insulin-sensitive, exercises, and has no metabolic dysfunction. And he explains what GLP-1 agonists are doing inside the brain completely independent of weight loss — targeting amyloid and tau through mechanisms that have nothing to do with appetite.
We also cover: the sardine diet experiment and omega-3 thermogenesis, ketones as misfolded protein clearance agents, creatine for depression, BPC-157 risks, retatrutide and PCSK9, the glymphatic system and 40Hz devices, and why Nick believes CRISPR prime editing will make ApoE4 a treatable condition within the next decade.
Watch this episode with Nick Norwitz to find out.
TOPICS DISCUSSED
00:00 Intro: The ApoE4 Paradox and the Case Report That Broke the Internet
00:57 Why Standard Omega-3 Supplements Fail and What to Take Instead
05:13 DHA and the Phospholipid Carrier: How It Crosses the Blood-Brain Barrier
10:19 ApoE4 Explained: Risk, Genetics, and Why Nick Is Optimistic
17:38 Why ApoE4 Carriers Burn Through DHA Faster and Need More
20:31 Women, Omega-3s, Menopause, and Brain Insulin Resistance
21:41 Statins, Sex Differences, and the DHA-Blood Sugar Connection
26:01 Statins and Dementia: What the Data Actually Say
32:24 Tau, GSK-3 Beta, Lithium Orotate, and Targeting Alzheimer's Pathology
42:19 The Glymphatic System, 40Hz Devices, and Sleep as Brain Clearance
45:21 Gene Editing, Prime Editing, and the Future of ApoE4 Therapy
49:33 Nick's Case Report: 700 LDL, Zero Plaque, and Seven Years of Data
55:10 The EZPAVE Trial: Why the Headlines Don't Hold Up
01:00:33 KetoneIQ: Ketones for Brain Energy and Focus
01:01:29 Cheers Health: Supporting Liver Function and Cognitive Recovery
01:03:54 If Not LDL, What Causes Heart Disease in Metabolically Healthy People?
01:12:05 The Oreo Experiment and the Sardine Diet: Self-Experiments in Metabolism
01:19:10 Ketones, Women's Brains, and Clearing Misfolded Proteins
01:21:08 The Full Brain Health Protocol: Omega-3s, Creatine, NAD, Lithium, and More
01:24:01 GLP-1s for the Brain: Independent of Weight, Targeting Amyloid and Tau
01:25:28 Peptides: BPC-157 Risks, Retatrutide, MOTS-c, and What's Worth Watching
01:29:02 Why Nick Is Controversial And Why He Doesn't Mind
This newsletter is brought to you by Function Health
When was the last time you measured your health instead of assuming it?
Many of the processes that contribute to cardiovascular disease, metabolic dysfunction, and other chronic conditions can develop for years before symptoms appear.
That is why biomarkers matter.
ApoB and Lipoprotein(a) [Lp(a)] can provide important insight into cardiovascular risk.
Fasting insulin, HOMA-IR, fasting glucose, and HbA1c help assess blood sugar regulation and metabolic health.
hs-CRP, eGFR, creatinine, ALT, AST, TSH, and Free T4 provide information about inflammation, kidney function, liver health, and thyroid function.
The goal is not simply to detect disease. It is to understand your health status early enough to make informed decisions.
That is why I like Function Health.
Their comprehensive testing platform measures 100+ lab tests annually, giving you a broader view of your health and helping guide decisions around nutrition, exercise, recovery, and long-term wellness.
You cannot manage what you do not measure.
If you are serious about performance, longevity, and preventive health, check it out and sign up using my code below.
